Table 4.

Multivariable Cox regression analysis for predicting vessel-oriented composite endpoint (n = 20).

	HR (95% CI)	P
Model a1
Post-procedural μQFR	5.94 (2.33–15.09)	< 0.001
Diabetes mellitus	2.64 (1.03–6.78)	0.04
Difference of DCB diameter and RVD (per 0.10-mm increase)	1.34 (1.10–1.62)	0.003
Model a2
Post-procedural μQFR (per 0.10-mm increase)	0.34 (0.23–0.51)	< 0.001
Diabetes mellitus	1.61 (0.55–4.66)	0.16
Difference of DCB diameter and RVD (per 0.10-mm increase)	1.25 (1.03–1.50)	0.02
Model b1
μQFR improvement	3.75 (1.31–10.68)	0.01
Diabetes mellitus	3.15 (1.23–8.05)	0.02
Residual lesion after DCB treatment	3.12 (1.21–8.03)	0.02
Difference of DCB diameter and RVD (per 0.10-mm increase)	1.33 (1.11–1.59)	0.002
Model b2
μQFR improvement (per 0.10-mm increase)	1.31 (1.04–1.66)	0.02
Diabetes mellitus	3.10 (1.21–7.92)	0.02
Residual lesion after DCB treatment	3.75 (1.47–9.56)	0.01
Difference of DCB diameter and RVD (per 0.10-mm increase)	1.32 (1.11–1.57)	0.001

Independent predictors of the previous analysis were used in time-to-event analysis fitting Cox regression models with forward likelihood ratio variable selection method; p values less than 0.05 are in bold; CI — confidence interval; HR — hazard ratio; DCB — drug-coated balloon; RVD — reference vessel diameter; μQFR — Murray law-based quantitative flow ratio